Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Active-controlled, Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density

NCT00577837 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00577837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00577837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Active-controlled, Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density
Lead sponsor
Warner Chilcott
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
June 30, 2005
Enrollment
370 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal